Boehmeria Nivea Extract (BNE-RRC) Reverses Epithelial-Mesenchymal Transition and Inhibits Anchorage-Independent Growth in Tumor Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Sep 14

PMID 39273519

Authors

Shiow-Ling Chen

Suh-Woan Hu

Yuh-Yih Lin

Wen-Li Liao

Jaw-Ji Yang

Affiliations

Soon will be listed here.

Abstract

The epithelial-mesenchymal transition (EMT) phenotype, identified as a significant clinical indicator in regard to cancer, manifests as a biological process wherein cells transition from having epithelial to mesenchymal characteristics. Physiologically, EMT plays a crucial role in tissue remodeling, promoting healing, repair, and responses to various types of tissue damage. This study investigated the impact of BNE-RRC on oral cancer cells (KB) and revealed its significant effects on cancer cell growth, migration, invasion, and the EMT. BNE-RRC induces the epithelial-like morphology in KB cells, effectively reversing the EMT to a mesenchymal-epithelial transition (MET). Extraordinarily, sustained culturing of cancer cells with BNE-RRC for 14 days maintains an epithelial status even after treatment withdrawal, suggesting that BNE-RRC is a potential therapeutic agent for cancer. These findings highlight the promise of BNE-RRC as a comprehensive therapeutic agent for cancer treatment that acts by inhibiting cancer cell growth, migration, and invasion while also orchestrating a reversal of the EMT process. In this study, we propose that BNE-RRC could be an effective agent for cancer treatment.

References

Xu Z, Zhang Y, Dai H, Han B . Epithelial-Mesenchymal Transition-Mediated Tumor Therapeutic Resistance. Molecules. 2022; 27(15). PMC: 9331826. DOI: 10.3390/molecules27154750. View

Heery R, Finn S, Cuffe S, Gray S . Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. Cancers (Basel). 2017; 9(4). PMC: 5406713. DOI: 10.3390/cancers9040038. View

Du B, Shim J . Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016; 21(7). PMC: 6273543. DOI: 10.3390/molecules21070965. View

Cordon-Cardo C, Prives C . At the crossroads of inflammation and tumorigenesis. J Exp Med. 1999; 190(10):1367-70. PMC: 2195699. DOI: 10.1084/jem.190.10.1367. View

Talbot L, Bhattacharya S, Kuo P . Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol. 2012; 3(2):117-36. PMC: 3388731. View

Yee D, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S . The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer. 2010; 9:162. PMC: 2907330. DOI: 10.1186/1476-4598-9-162. View

Choi J, Nguyen Q, Baek J, Cho D, Kang K, Hahm D . Beneficial role of Boehmeria nivea in health and phytochemical constituents. J Food Biochem. 2022; 46(12):e14474. DOI: 10.1111/jfbc.14474. View

Zhang J, Hu Z, Horta C, Yang J . Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. Semin Cancer Biol. 2022; 88:46-66. PMC: 10237282. DOI: 10.1016/j.semcancer.2022.12.002. View

Kumar V, Vashishta M, Kong L, Wu X, Lu J, Guha C . The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. Front Cell Dev Biol. 2021; 9:650772. PMC: 8100510. DOI: 10.3389/fcell.2021.650772. View

10.

Takkunen M, Grenman R, Hukkanen M, Korhonen M, Garcia de Herreros A, Virtanen I . Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. J Histochem Cytochem. 2006; 54(11):1263-75. DOI: 10.1369/jhc.6A6958.2006. View

11.

McCubrey J, Lertpiriyapong K, Steelman L, Abrams S, Yang L, Murata R . Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY). 2017; 9(6):1477-1536. PMC: 5509453. DOI: 10.18632/aging.101250. View

12.

Lewis-Tuffin L, Rodriguez F, Giannini C, Scheithauer B, Necela B, Sarkaria J . Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One. 2010; 5(10):e13665. PMC: 2965143. DOI: 10.1371/journal.pone.0013665. View

13.

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J . The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000; 2(2):84-9. DOI: 10.1038/35000034. View

14.

Zhang Y, Weinberg R . Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018; 12(4):361-373. PMC: 6186394. DOI: 10.1007/s11684-018-0656-6. View

15.

Sha J, Bai Y, Ngo H, Okui T, Kanno T . Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition. Biomolecules. 2021; 11(6). PMC: 8234904. DOI: 10.3390/biom11060893. View

16.

Wu Y, Sarkissyan M, Vadgama J . Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med. 2016; 5(2). PMC: 4773769. DOI: 10.3390/jcm5020013. View

17.

Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E . The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001; 7(6):1267-78. DOI: 10.1016/s1097-2765(01)00260-x. View

18.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

19.

Anwar S, Malik J, Ahmed S, Kameshwar V, Alanazi J, Alamri A . Can Natural Products Targeting EMT Serve as the Future Anticancer Therapeutics?. Molecules. 2022; 27(22). PMC: 9698579. DOI: 10.3390/molecules27227668. View

20.

Brabletz S, Schuhwerk H, Brabletz T, Stemmler M . Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021; 40(18):e108647. PMC: 8441439. DOI: 10.15252/embj.2021108647. View